$RAPH
Raphael Pharmaceutical Inc.

2021 Q4 Form 10-K Financial Statement

#000121390022015973 Filed on March 30, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $850.0K
YoY Change
% of Gross Profit
Research & Development $780.0K
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.630M
YoY Change
Operating Profit -$1.629M
YoY Change
Interest Expense $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $5.000K
YoY Change
Pretax Income -$1.630M
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$1.630M
YoY Change
Net Earnings / Revenue
Basic Earnings Per Share $0.14
Diluted Earnings Per Share -$145.9K
COMMON SHARES
Basic Shares Outstanding 11.17M shares
Diluted Shares Outstanding 11.17M shares

Balance Sheet

Concept 2021 Q4 2021 2020
SHORT-TERM ASSETS
Cash & Short-Term Investments $150.0K
YoY Change
Cash & Equivalents $153.0K $150.0K
Short-Term Investments
Other Short-Term Assets $269.0K $270.0K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $422.0K $420.0K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $422.0K $420.0K
Total Long-Term Assets $0.00 $0.00
Total Assets $422.0K $420.0K
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $165.0K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $20.00K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $294.0K $290.0K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $294.0K $290.0K
Total Long-Term Liabilities $0.00
Total Liabilities $290.0K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$2.667M
YoY Change
Common Stock $130.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $128.0K $130.0K
YoY Change
Total Liabilities & Shareholders Equity $422.0K $420.0K
YoY Change

Cashflow Statement

Concept 2021 Q4 2021 2020
OPERATING ACTIVITIES
Net Income -$1.630M
YoY Change
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.420M
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.480M
YoY Change
NET CHANGE
Cash From Operating Activities -1.420M
Cash From Investing Activities
Cash From Financing Activities 1.480M
Net Change In Cash 60.00K
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$1.420M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11171704 shares
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9459253 shares
CY2021Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
208000 USD
CY2021Q2 dei Entity Public Float
EntityPublicFloat
0 USD
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-43000 USD
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-43000 USD
CY2021Q4 us-gaap Other Notes Payable
OtherNotesPayable
22000 USD
CY2020Q4 us-gaap Other Notes Payable
OtherNotesPayable
10000 USD
CY2021 us-gaap Professional Fees
ProfessionalFees
120000 USD
CY2020 us-gaap Professional Fees
ProfessionalFees
110000 USD
CY2021 us-gaap Legal Fees
LegalFees
75000 USD
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
USD
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
21020560 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
21020560 shares
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
USD
CY2020 cik0000141539 Cash Acquired In The Reverse Recapitalization
CashAcquiredInTheReverseRecapitalization
USD
CY2020 cik0000141539 Non Cash Issuance Costs
NonCashIssuanceCosts
USD
CY2020 cik0000141539 Current Assetsexcluding Cash And Cash Equivalents
CurrentAssetsexcludingCashAndCashEquivalents
USD
CY2020 cik0000141539 Current Liabilities
CurrentLiabilities
USD
CY2020 cik0000141539 Reverse Recapitalization Effect On Equity
ReverseRecapitalizationEffectOnEquity
USD
CY2020 cik0000141539 Cash Acquired In Connection With Reverse Recapitalization Transaction
CashAcquiredInConnectionWithReverseRecapitalizationTransaction
USD
CY2020Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
USD
CY2020 us-gaap Legal Fees
LegalFees
USD
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
USD
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
USD
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD

Files In Submission

Name View Source Status
0001213900-22-015973-index-headers.html Edgar Link pending
0001213900-22-015973-index.html Edgar Link pending
0001213900-22-015973.txt Edgar Link pending
0001213900-22-015973-xbrl.zip Edgar Link pending
cik0000141539-20211231.xsd Edgar Link pending
cik0000141539-20211231_cal.xml Edgar Link unprocessable
cik0000141539-20211231_def.xml Edgar Link unprocessable
cik0000141539-20211231_lab.xml Edgar Link unprocessable
cik0000141539-20211231_pre.xml Edgar Link unprocessable
f10k2021ex31-1_raphael.htm Edgar Link pending
f10k2021ex31-2_raphael.htm Edgar Link pending
f10k2021ex32-1_raphael.htm Edgar Link pending
f10k2021ex32-2_raphael.htm Edgar Link pending
f10k2021ex4-1_raphael.htm Edgar Link pending
f10k2021_raphaelpharma.htm Edgar Link pending
f10k2021_raphaelpharma_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
image_002.jpg Edgar Link pending
image_003.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending